Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTargeting host factors: A novel rationale for the management of hepatitis C virus
World Journal of Gastroenterology, 07/27/09
Khattab MA – Hepatitis C is recognized as a major threat to global public health. The current treatment of patients with chronic hepatitis C is the addition of ribavirin to interferon–based therapy which has limited efficacy, poor tolerability, and significant expense. New treatment options that are more potent and less toxic are much needed.
Related Articles
Rationale against Preoperative Screening for HIV in Polish Hospitals: A Prevalence Study of Anti-HIV in Contrast to Anti-Hepatitis C Virus and Hepatitis B Surface Antigen
Infection Control and Hospital Epidemiology, 11/11/09
Relevance Score: 82%
De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation
Liver Transplantation, 10/30/09
Relevance Score: 82%
The HLA-ER/HLA-ER Genotype Affects the Natural Course of Hepatitis C Virus (HCV) Infection and Is Associated with HLA-E–Restricted Recognition of an HCV-Derived Peptide by Interferon[gamma]–Secreting Human CD8+ T Cells
The Journal of Infectious Diseases, 10/14/09
Relevance Score: 82%
FOXP3 Expression in Hepatitis C Virus-Specific CD4+ T Cells During Acute Hepatitis C
Gastroenterology, 10/06/09
Relevance Score: 82%
Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus
Journal of Gastroenterology, 10/02/09
Relevance Score: 82%
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Role of free radicals in liver diseases
Hepatology International, 12/02/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Optimizing the treatment of chronic viral hepatitis C
Expert Review of Gastroenterology & Hepatology, 11/30/09
Sponsor
Article Search
Sponsor